Prolonged in-vivo half-life of factor VIIa by fusion to albumin

Thrombosis and Haemostasis

Volumn 99, Issue 4, 2008, Pages 659-667

  Weimer, Thomas ^a   Wormsbächer, Wilfried ^a   Kronthaler, Ulrich ^a   Lang, Wiegand ^a   Liebing, Uwe ^a   Schulte, Stefan ^a  

^a CSL BEHRING GMBH   (Germany)

Author keywords

Albumin fusion; Coagulation; FVIIa; rVIIa FP

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; HUMAN ALBUMIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 7A HUMAN ALBUMIN FUSION PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; EMBRYO; FEASIBILITY STUDY; HEMOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAMMAL CELL; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WILD TYPE;

ANIMALS; BASE SEQUENCE; COAGULANTS; DNA, RECOMBINANT; FACTOR VIIA; HALF-LIFE; HEMOPHILIA A; HEMOSTASIS; HUMANS; PROTEIN BINDING; PROTEIN ENGINEERING; RATS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; SERUM ALBUMIN; SURFACE PLASMON RESONANCE; THROMBELASTOGRAPHY; THROMBOPLASTIN;

EID: 43749102313     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-08-0525     Document Type: Article

References (38)

1. Greenberg DL, Davie EW. Blood coagulation factors: Their complementary DNAs, genes and expression. In: Hemostasis and Thrombosis. Philadelphia: Lippincott Williams & Wilkins 2001; 135-15 6.
2. Wildgoose P, Nemerson Y, Hansen LL, et al. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992; 80: 25-28.
3. Hedner U. Recombinant activated factor VII as universal haemostatic agent. Blood Coag Fibrinolysis 1998; 9 Suppl 1: S147-152.
4. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia 1998; 4: 790-798.
5. Butenas S, Brummel KE, Bouchard BA, et al. How factor VIIa works in hemophilia. J Thromb Haemost 2003; 1: 1158-1160.
6. Roberts HR, Monroe DR, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-3864.
7. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (VIIa). Semin Thromb Hemost 2000; 26: 385-391.
8. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant Factor VIIa (Novoseven) in hemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-918.
9. Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2006; 109: 546-551.
10. Lusher JM. Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Hemostasis 1996; 26 (Suppl 1): 124-130.
11. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomized trial for two doses of rFVIIa (Novoseven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-778.
12. Dumont JA, Low SC, Peters RT, et al. Monomeric Fc fusions: Impact on pharmacokinetics and biological activity of protein therapeutics. BioDrugs 2006; 20: 151-160.
13. Chuang VTG, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 2002; 5: 569-577.
14. Sterling K. The turnover rate of serum albumin in man as measured by I-131-tagged albumin. J Clin Invest 1957; 30: 1228-1237.
15. Sheffield WP, Smith IJ, Syed S, et al. Prolonged in vivo anticoagulant activity of a hirudin-albumin fusion protein secreted from Pichia pastoris. Blood Coag Fibrinol 2001; 12: 433-443.
16. Duttaroy A, Kanakaraj P, Osborn BL, et al. Development of a long-acting insulin analog using albumin fusion technology. Diabetes 2005; 54: 251-258.
17. Wang W, Ou Y, Shi Y. AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm Res 2004; 21: 2105-2111.
18. Osborn BL, Olsen HS, Nardelli B, et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-α fusion protein in Cynomolgus monkeys. J Pharmacol Exp Ther 2002; 303: 540-548.
19. Bain VG, Kaita KD, Yoshida EM, et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006; 44: 671-678.
20. Balan V, Nelson DR, Sulkowski MS, et al. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther 2006; 11: 35-45.
21. Sheffield WP, Mamdani A, Hortelano G, et al. Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. Br J Haematol 2004; 126: 565-573.
22. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6: 539-546.
23. Bjoern S, Thim L. Activation of coagulation factor VII to VIIa. Res Disclosure 1986; 564-565.
24. Pedersen AH, Lund-Hansen T, Bisgaard-Frantzen H, et al. Autoactivation of human recombinant coagulation FVII. Biochemistry 1989; 28: 9331-9336.
25. Mollerup I, Bayne S, Halkjaer E, et al. The use of RP-HPLC for measuring activation and cleavage of rFVIIa during purification. Biotechnol Bioeng 1995; 48: 501-505.
26. Mann KG, Butenas S, Brummel K. The dynamics of Thrombin formation. Arterioscler Thromb Vasc Biol 2003; 23: 17-25.
27. Hoffmann M, Monroe DM. Coagulation 2006: A modern view of hemostasis. Hematol Oncol Clin N Am 2007; 21: 1-11.
28. Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res 2007; 119: 643-651.
29. Persson E, Kjalke M, Olsen OH. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci USA 2001; 98: 13583-13588.
30. Persson E, Bak H, Olsen OH. Substitution of Valine for Leucine 305 in Factor VIIa increases the intrinsic enzymatic activity. J Biol Chem 2001; 276: 29195-29199.
31. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969; 13: 1-110.
32. Chaudhury C, Mehnaz S, Robinson JM, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 2003; 197: 315-322.
33. Anderson CL, Chaudhury C, Kim J, et al. Perspective - FcRn transports albumin: relevance to immunology and medicine. Trends in Immunology 2006; 7: 343-348.
34. Ewenstein BM, Joist JH, Shapiro AD, et al. Pharmacokinetic analysis of plasma-derived and recombinant FIX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190-197.
35. Ghosh S, Pendurthi UR, Steinoe A, et al. Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium. J Biol Chem 2007; 282: 11849-11857.
36. Wolberg AS, Stafford DW, Erie DA. Human FIX binds to specific sites on the collagenous domain of collagen IV. J Biol Chem 1997; 272: 16717-16720.
37. Cheung WF, van den Born J, Kühn K, et al. Identification of the endothelial binding site for FIX. Proc Natl Acad Sci USA 1996; 93: 11068-11073.
38. Gui T, Lin HF, Jin DY, Hoffmann M, et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood 2002; 100: 153-158.